Preferences help
enabled [disable] Abstract
Number of results
2014 | 4 | 4 | A148-A154
Article title

Administration of liposomal doxorubicin in patients with metastatic breast cancer and significant concomitant cardiovascular conditions

Title variants
Languages of publication
A frequent dilemma faced by an oncologist about to take decision on a chemotherapeutic regime for patients with metastatic breast cancer is how to maintain balance between the expected treatment efficacy and predictable adverse events. In the case of anthracyclines what is problematic is their significant cardiotoxicity, in particular with reference to patients previously treated with them as part of adjuvant therapy. A relatively new method is replacement of conventional doxorubicin with its non-pegylated form, encapsulated in liposomes, which is capable of minimizing the side effects without compromising its therapeutic index. The present article discusses three cases of patients treated with non-pegylated liposomal doxorubicin (NPLD) as first-line chemotherapy administered for metastatic breast cancer. In all three cases considerable clinical improvement was observed, involving remission of pathological lesions and good quality of life.
Physical description
  • Regional Oncology Centre in Lodz, Department of Chemotherapy, Copernicus Memorial Hospital in Lodz
  • Harris L, Batist GL, Belt R et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial et first-line therapy of metastatic breast carcinoma. Cancer 2002; 94: 25-36.
  • Batist G, Remakrishnan G, Rao CS et al. Reduced cardiotoxity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin with cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 2001; 19: 1444-1454.
  • Batist G, Harris L, Azarina N et al. Improved anti-tumor response rate with decreased cardiotoxity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who haved received prior adjuvant doxorubicin: results of a retrospective analysys. Anticancer Drugs 2006; 17: 587-595.
  • Barett-Lee PJ, Dixon JM, Farrell C et al. Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk. Ann Oncol 2009; 19: 1-11.
  • Morabito A, Piccirillo MC, Monaco K et al. First-line chemotherapy for HER-negative metastatic breast cancer patients who received anthracyclines as adjuvant treatment. Oncologist 2007; 12: 1288-1298.
  • Lord S, Ghersi D, Gattellari M et al. Antitumor antibiotic containing regimens for metastatic breast cancer. Cochrane Database Syst Rev 2004.
  • Van Dalen EC, Michiels EM, Caron HN et al. Different anthracycline derivates for reducing cardiotoxity in cancers patients. Cochrane Databases Syst Rev 2006; 4: CD005 006. Update in: Cochrane Database Syst Rev 2010.
  • Al-Bartan SE, Bischoff J, von Minckwitz G et al. The clinical benefit of pegylated liposomal doxorubicin in patients with conventional anthracyclines: a multicancer phase II trial. Br J Cancer 2006; 94: 1615-1620.
  • Jones RL, Swanton C, Ewe MS. Anthracycline cardiotoxicity. Expert Opin Drug Saf 2006; 5(6): 791-809.
  • Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patient treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003; 97(11): 2869-2879.
  • O’Shaughnessy J, Twelves C, Aapro M. Treatment for anthracycline-pretreated metastatic breast cancer. Oncologist 2002; 7: 4-12.
  • Al-Bartan SE, Guntner M, Pauglik C et al. Anthracyclines rechallenge using pegylated liposomal doxorubicin in patients with metastatic breast cancer: a pooled analysis using individual data four prospective trials. Br J Cancer 2010; 103: 1518-1523.13.
  • Martin F, Boulikas T. The challenge of liposomes in gene therapy. Gene Ther Mol Biol 1998; 1: 173-214.
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.